<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://onlinelibrarystatic.wiley.com/xslt/wol-journal-rss.xsl"
            type="text/xsl"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1934-6638" xmlns="http://purl.org/rss/1.0/"><title>Cancer Cytopathology</title><description> Wiley Online Library : Cancer Cytopathology</description><link>http://dx.doi.org/10.1002%2F%28ISSN%291934-6638</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2012 American Cancer Society</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1934-662X</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1934-6638</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">25 February 2012</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">120</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">70</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/cncy.v120.1/asset/cover.gif?v=1&amp;s=62c2033eb0e4bda5e36855e66f8f1396cd835dea"/><items><rdf:Seq><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20206"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.21184"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.21185"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20207"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20205"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20199"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20197"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20195"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20191"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20192"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20184"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20187"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20178"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20181"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.21187"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20196"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20186"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20175"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20188"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20185"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20179"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20180"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fcncy.20167"/></rdf:Seq></items></channel><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20206" xmlns="http://purl.org/rss/1.0/"><title>Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma</title><link>http://dx.doi.org/10.1002%2Fcncy.20206</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Enrico Pegolo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Piernicola Machin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Franca Riosa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Bassini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Deroma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carla Di Loreto</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T11:07:14.848367-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20206</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20206</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20206</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Fine-needle aspiration cytology (FNAC) is a well-accepted procedure for the diagnosis and biological characterization of breast carcinoma. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status have a strong prognostic and predictive value in invasive breast carcinoma (IBC). ThinPrep (TP) cytology, which uses an alcohol-based fixative, is increasingly being used for immunocytochemistry. In this study, the authors compared the immunocytochemical evaluation of hormone receptors (HR) and HER2 on TP-processed FNAC with the immunohistochemical analysis performed on the corresponding formalin-fixed paraffin-embedded (FFPE) breast tumor specimens, which are considered the gold standard.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>FNACs were performed on 116 primary IBCs at the time of diagnosis and subjected to immunocytochemical evaluation of HR and HER2 using the TP method. The same markers were immunohistochemical evaluated on the corresponding FFPE tissue specimens. HER2 fluorescent in situ hybridization analysis was performed only on the equivocal immunohistochemical results.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>The HR results of the TP cytology specimens showed a very good agreement with those of the corresponding FFPE tissue samples (Cohen kappa test = 0.92; concordance rate = 98%) for estrogen receptor, and a good agreement (kappa = 0.76; concordance rate = 90.9%) for progesterone receptor. A perfect agreement (kappa = 1) was observed between TP and FFPE tissue samples in evaluating HER2 status.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Alcohol-based fixation seems not to affect the immunocytochemical evaluation of HR and HER2. Considering the high levels of agreement between the evaluation of HR and HER2, on both cytology specimens and on the corresponding FFPE tissue samples, the authors concluded that the TP technique can be routinely used for the biological characterization of IBC. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Fine-needle aspiration cytology (FNAC) is a well-accepted procedure for the diagnosis and biological characterization of breast carcinoma. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status have a strong prognostic and predictive value in invasive breast carcinoma (IBC). ThinPrep (TP) cytology, which uses an alcohol-based fixative, is increasingly being used for immunocytochemistry. In this study, the authors compared the immunocytochemical evaluation of hormone receptors (HR) and HER2 on TP-processed FNAC with the immunohistochemical analysis performed on the corresponding formalin-fixed paraffin-embedded (FFPE) breast tumor specimens, which are considered the gold standard.METHODS:FNACs were performed on 116 primary IBCs at the time of diagnosis and subjected to immunocytochemical evaluation of HR and HER2 using the TP method. The same markers were immunohistochemical evaluated on the corresponding FFPE tissue specimens. HER2 fluorescent in situ hybridization analysis was performed only on the equivocal immunohistochemical results.RESULTS:The HR results of the TP cytology specimens showed a very good agreement with those of the corresponding FFPE tissue samples (Cohen kappa test = 0.92; concordance rate = 98%) for estrogen receptor, and a good agreement (kappa = 0.76; concordance rate = 90.9%) for progesterone receptor. A perfect agreement (kappa = 1) was observed between TP and FFPE tissue samples in evaluating HER2 status.CONCLUSIONS:Alcohol-based fixation seems not to affect the immunocytochemical evaluation of HR and HER2. Considering the high levels of agreement between the evaluation of HR and HER2, on both cytology specimens and on the corresponding FFPE tissue samples, the authors concluded that the TP technique can be routinely used for the biological characterization of IBC. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.21184" xmlns="http://purl.org/rss/1.0/"><title>Arginase-1: A novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology</title><link>http://dx.doi.org/10.1002%2Fcncy.21184</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Arginase-1: A novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ryan McKnight</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aziza Nassar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cynthia Cohen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Momin T. Siddiqui</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T11:06:59.988592-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21184</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21184</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.21184</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Arginase-I is a key urea cycle metalloenzyme that has been used as an immunohistochemistry (IHC) marker for hepatocellular carcinoma (HCC). Previous studies have demonstrated the efficacy of HepPar-1 and glypican-3 (GPC-3) IHC in liver fine needle aspiration (FNA) cytology.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Arginase-1 IHC was performed on FNA cell blocks, and its performance characteristics were compared with HepPar-1 and GPC-3. Ninety-two formalin-fixed, paraffin-embedded cell blocks were selected (HCC [n = 44], cirrhosis [n = 2], focal nodular hyperplasia [n = 3], hepatic adenomas [n = 2], dysplastic nodules [n = 6], and metastatic carcinomas [n = 35]). IHC staining with antibodies directed against arginase-1, HepPar-1, and GPC-3 was performed with appropriate positive and negative controls.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Arginase-1 positivity was demonstrated in 37 of 44 (84.1%) cases of HCC, compared with 32 of 44 cases (72.7%) and 25 of 44 cases (56.8%) for HepPar-1 and GPC-3, respectively. Arginase-1 and GPC-3 expression were not observed in any cases of metastatic carcinoma (0%), whereas HepPar-1 expression was present in 1 case of metastatic carcinoma. In addition, both arginase-1 and HepPar-1 expression were present in all 13 cases (100%) of nonmalignant hepatocellular lesions, whereas GPC-3 expression was absent in all 13 cases (0%).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSION:</h3><div class="para"><p>This study demonstrates that both arginase-1 and HepPar-1 are effective IHC markers of hepatocellular differentiation. Furthermore, arginase-1 demonstrates superior sensitivity compared with GPC-3 and HepPar-1 in the diagnosis of HCC, whereas GPC-3 demonstrates superior specificity, as staining is not observed in benign hepatocellular lesions. Hence, use of arginase-1 with HepPar-1 and GPC-3 can aid in the diagnosis of HCC and separating from metastatic carcinoma. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Arginase-I is a key urea cycle metalloenzyme that has been used as an immunohistochemistry (IHC) marker for hepatocellular carcinoma (HCC). Previous studies have demonstrated the efficacy of HepPar-1 and glypican-3 (GPC-3) IHC in liver fine needle aspiration (FNA) cytology.METHODS:Arginase-1 IHC was performed on FNA cell blocks, and its performance characteristics were compared with HepPar-1 and GPC-3. Ninety-two formalin-fixed, paraffin-embedded cell blocks were selected (HCC [n = 44], cirrhosis [n = 2], focal nodular hyperplasia [n = 3], hepatic adenomas [n = 2], dysplastic nodules [n = 6], and metastatic carcinomas [n = 35]). IHC staining with antibodies directed against arginase-1, HepPar-1, and GPC-3 was performed with appropriate positive and negative controls.RESULTS:Arginase-1 positivity was demonstrated in 37 of 44 (84.1%) cases of HCC, compared with 32 of 44 cases (72.7%) and 25 of 44 cases (56.8%) for HepPar-1 and GPC-3, respectively. Arginase-1 and GPC-3 expression were not observed in any cases of metastatic carcinoma (0%), whereas HepPar-1 expression was present in 1 case of metastatic carcinoma. In addition, both arginase-1 and HepPar-1 expression were present in all 13 cases (100%) of nonmalignant hepatocellular lesions, whereas GPC-3 expression was absent in all 13 cases (0%).CONCLUSION:This study demonstrates that both arginase-1 and HepPar-1 are effective IHC markers of hepatocellular differentiation. Furthermore, arginase-1 demonstrates superior sensitivity compared with GPC-3 and HepPar-1 in the diagnosis of HCC, whereas GPC-3 demonstrates superior specificity, as staining is not observed in benign hepatocellular lesions. Hence, use of arginase-1 with HepPar-1 and GPC-3 can aid in the diagnosis of HCC and separating from metastatic carcinoma. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.21185" xmlns="http://purl.org/rss/1.0/"><title>Fine needle aspiration of intrapancreatic accessory spleen: Cytomorphologic features and differential diagnosis</title><link>http://dx.doi.org/10.1002%2Fcncy.21185</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Fine needle aspiration of intrapancreatic accessory spleen: Cytomorphologic features and differential diagnosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Armanda D. Tatsas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christopher L. Owens</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Momin T. Siddiqui</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ralph H. Hruban</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Syed Z. Ali</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T11:06:33.152069-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21185</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21185</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.21185</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Intrapancreatic accessory spleen (IPAS) is a rare benign lesion of the pancreas that frequently clinically and radiographically mimics a solid neoplasm. Very rarely, epidermoid cysts may form in IPAS and be mistaken for a cystic neoplasm of the pancreas on radiographic imaging. IPAS and epidermoid cyst involving intrapancreatic cyst (ECIPAS) are benign, and, if recognized, do not require surgical intervention. There are few reports of the cytopathologic features of IPAS diagnosed by fine needle aspiration (FNA).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Here we report a series of 6 cases of endoscopic ultrasound (EUS)-guided FNA of IPAS, 3 of which had histological confirmation, including 1 case of histologically confirmed ECIPAS.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Cytomorphologic features of IPAS include a polymorphous population of hematopoietic cells, including lymphocytes, eosinophils, histiocytes, plasma cells, and red blood cells, admixed with numerous small blood vessels representing splenic sinusoids. CD8 immunostaining of cell block or core biopsy material highlights splenic endothelial cells and confirms the diagnosis. FNA of ECIPAS reveals predominantly macrophages and proteinaceous debris.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Diagnostic pitfalls include pancreatic neuroendocrine tumor. If IPAS is recognized as a diagnostic consideration on EUS-FNA, unnecessary surgical resection may be avoided. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Intrapancreatic accessory spleen (IPAS) is a rare benign lesion of the pancreas that frequently clinically and radiographically mimics a solid neoplasm. Very rarely, epidermoid cysts may form in IPAS and be mistaken for a cystic neoplasm of the pancreas on radiographic imaging. IPAS and epidermoid cyst involving intrapancreatic cyst (ECIPAS) are benign, and, if recognized, do not require surgical intervention. There are few reports of the cytopathologic features of IPAS diagnosed by fine needle aspiration (FNA).METHODS:Here we report a series of 6 cases of endoscopic ultrasound (EUS)-guided FNA of IPAS, 3 of which had histological confirmation, including 1 case of histologically confirmed ECIPAS.RESULTS:Cytomorphologic features of IPAS include a polymorphous population of hematopoietic cells, including lymphocytes, eosinophils, histiocytes, plasma cells, and red blood cells, admixed with numerous small blood vessels representing splenic sinusoids. CD8 immunostaining of cell block or core biopsy material highlights splenic endothelial cells and confirms the diagnosis. FNA of ECIPAS reveals predominantly macrophages and proteinaceous debris.CONCLUSIONS:Diagnostic pitfalls include pancreatic neuroendocrine tumor. If IPAS is recognized as a diagnostic consideration on EUS-FNA, unnecessary surgical resection may be avoided. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20207" xmlns="http://purl.org/rss/1.0/"><title>The emerging role of circulating tumor cells in breast cancer</title><link>http://dx.doi.org/10.1002%2Fcncy.20207</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The emerging role of circulating tumor cells in breast cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Savitri Krishnamurthy</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-24T15:36:52.850561-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20207</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20207</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20207</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Commentary</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The evaluation of circulating tumor cells in peripheral blood of patients with breast cancer can be performed using different platforms. Standardization and comparison of the platforms to each other and their use in prospective clinical trials is needed for incorporation of circulating tumor cell assays into clinical practice.</p></div>]]></content:encoded><description>The evaluation of circulating tumor cells in peripheral blood of patients with breast cancer can be performed using different platforms. Standardization and comparison of the platforms to each other and their use in prospective clinical trials is needed for incorporation of circulating tumor cell assays into clinical practice.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20205" xmlns="http://purl.org/rss/1.0/"><title>The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis</title><link>http://dx.doi.org/10.1002%2Fcncy.20205</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauro Ajaj Saieg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William R. Geddie</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Scott L. Boerner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ni Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ming Tsao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tong Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Suzanne Kamel-Reid</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gilda da Cunha Santos</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-24T15:36:16.952709-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20205</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20205</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20205</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Novel high-throughput molecular technologies have made the collection and storage of cells and small tissue specimens a critical issue. The FTA card provides an alternative to cryopreservation for biobanking fresh unfixed cells. The current study compared the quality and integrity of the DNA obtained from 2 types of FTA cards (Classic and Elute) using 2 different extraction protocols (“Classic” and “Elute”) and assessed the feasibility of performing multiplex mutational screening using fine-needle aspiration (FNA) biopsy samples.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Residual material from 42 FNA biopsies was collected in the cards (21 Classic and 21 Elute cards). DNA was extracted using the Classic protocol for Classic cards and both protocols for Elute cards. Polymerase chain reaction for <em>p53</em> (1.5 kilobase) and <em>CARD11</em> (500 base pair) was performed to assess DNA integrity.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Successful <em>p53</em> amplification was achieved in 95.2% of the samples from the Classic cards and in 80.9% of the samples from the Elute cards using the Classic protocol and 28.5% using the Elute protocol (<em>P</em> = .001). All samples (both cards) could be amplified for <em>CARD11</em>. There was no significant difference in the DNA concentration or 260/280 purity ratio when the 2 types of cards were compared. Five samples were also successfully analyzed by multiplex MassARRAY spectrometry, with a mutation in <em>KRAS</em> found in 1 case.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>High molecular weight DNA was extracted from the cards in sufficient amounts and quality to perform high-throughput multiplex mutation assays. The results of the current study also suggest that FTA Classic cards preserve better DNA integrity for molecular applications compared with the FTA Elute cards. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Novel high-throughput molecular technologies have made the collection and storage of cells and small tissue specimens a critical issue. The FTA card provides an alternative to cryopreservation for biobanking fresh unfixed cells. The current study compared the quality and integrity of the DNA obtained from 2 types of FTA cards (Classic and Elute) using 2 different extraction protocols (“Classic” and “Elute”) and assessed the feasibility of performing multiplex mutational screening using fine-needle aspiration (FNA) biopsy samples.METHODS:Residual material from 42 FNA biopsies was collected in the cards (21 Classic and 21 Elute cards). DNA was extracted using the Classic protocol for Classic cards and both protocols for Elute cards. Polymerase chain reaction for p53 (1.5 kilobase) and CARD11 (500 base pair) was performed to assess DNA integrity.RESULTS:Successful p53 amplification was achieved in 95.2% of the samples from the Classic cards and in 80.9% of the samples from the Elute cards using the Classic protocol and 28.5% using the Elute protocol (P = .001). All samples (both cards) could be amplified for CARD11. There was no significant difference in the DNA concentration or 260/280 purity ratio when the 2 types of cards were compared. Five samples were also successfully analyzed by multiplex MassARRAY spectrometry, with a mutation in KRAS found in 1 case.CONCLUSIONS:High molecular weight DNA was extracted from the cards in sufficient amounts and quality to perform high-throughput multiplex mutation assays. The results of the current study also suggest that FTA Classic cards preserve better DNA integrity for molecular applications compared with the FTA Elute cards. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20199" xmlns="http://purl.org/rss/1.0/"><title>Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration</title><link>http://dx.doi.org/10.1002%2Fcncy.20199</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rex Chin Wei Yung</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susan Otell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter Illei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Douglas P. Clark</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Feller-Kopman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lonny Yarmus</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Frederic Askin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edward Gabrielson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qing Kay Li</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T11:01:10.683425-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20199</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20199</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20199</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Cell block (CB) preparation during the endobronchial ultrasound-guided transbronchial fine-needle aspiration (EBUS-TBNA) procedure plays an important role in the diagnosis of lung cancer and recovery of cellular material for molecular characterization of the tumor. However, the efficiency of the conventional method of CB preparation is suboptimal.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>In the current study, the “tissue coagulum clot” cell block (TCC-CB) method was used to prepare the CBs and its efficiency was compared with that of the conventional saline rinse cell block (NR-CB) method. A total of 84 consecutive TCC-CBs (106 lymph nodes [LNs] and 14 lung lesions) and 28 consecutive cases of NR-CB (39 LNs and 3 lung lesions) obtained within the same time period were included in the current study.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>In the TCC-CB specimens, 94 of 106 LN cases (88.7%) yielded sufficient diagnostic material, as did 11 of 14 lung lesions (78.6%). In the NR-CB group, which was used as the control, 22 of 39 LN specimens (56.4%) and none of 3 lung specimens (0%) were found to provide sufficient diagnostic material. Although the average size of the LNs in the study group were not significantly different from those in the control group (1.76 cm vs 1.82 cm; <em>P</em> &gt; .05), the overall nondiagnostic rates in the TCC-CB and NR-CB groups were 11.2% and 43.6%, respectively (<em>P</em> &lt; .001). The nondiagnostic rates of the lung specimens were 15.4% in the TCC-CB group and 100% in the NR-CB group (<em>P</em> &lt; .05). In addition, immunohistochemistry studies and epidermal growth factor receptor (<em>EGFR</em>)/<em>KRAS</em> mutational analyses were performed in 26 and 14 TCC-CB cases, respectively. With the exception of 1 case, all of them had satisfactory results.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>The data from the current study demonstrate that the TCC-CB method significantly increases the cellular yield of CB preparations without compromising cytomorphological characterization of tumor cells. <b><em>Cancer (Cancer Cytopathol)</em> 2011;.</b> © <em>2011 American Cancer Society</em>.</p></div></div>]]></content:encoded><description>BACKGROUND:Cell block (CB) preparation during the endobronchial ultrasound-guided transbronchial fine-needle aspiration (EBUS-TBNA) procedure plays an important role in the diagnosis of lung cancer and recovery of cellular material for molecular characterization of the tumor. However, the efficiency of the conventional method of CB preparation is suboptimal.METHODS:In the current study, the “tissue coagulum clot” cell block (TCC-CB) method was used to prepare the CBs and its efficiency was compared with that of the conventional saline rinse cell block (NR-CB) method. A total of 84 consecutive TCC-CBs (106 lymph nodes [LNs] and 14 lung lesions) and 28 consecutive cases of NR-CB (39 LNs and 3 lung lesions) obtained within the same time period were included in the current study.RESULTS:In the TCC-CB specimens, 94 of 106 LN cases (88.7%) yielded sufficient diagnostic material, as did 11 of 14 lung lesions (78.6%). In the NR-CB group, which was used as the control, 22 of 39 LN specimens (56.4%) and none of 3 lung specimens (0%) were found to provide sufficient diagnostic material. Although the average size of the LNs in the study group were not significantly different from those in the control group (1.76 cm vs 1.82 cm; P &gt; .05), the overall nondiagnostic rates in the TCC-CB and NR-CB groups were 11.2% and 43.6%, respectively (P &lt; .001). The nondiagnostic rates of the lung specimens were 15.4% in the TCC-CB group and 100% in the NR-CB group (P &lt; .05). In addition, immunohistochemistry studies and epidermal growth factor receptor (EGFR)/KRAS mutational analyses were performed in 26 and 14 TCC-CB cases, respectively. With the exception of 1 case, all of them had satisfactory results.CONCLUSIONS:The data from the current study demonstrate that the TCC-CB method significantly increases the cellular yield of CB preparations without compromising cytomorphological characterization of tumor cells. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20197" xmlns="http://purl.org/rss/1.0/"><title>Role of ancillary studies in fine-needle aspiration from selected tumors</title><link>http://dx.doi.org/10.1002%2Fcncy.20197</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Role of ancillary studies in fine-needle aspiration from selected tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fernando Schmitt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Helena Barroca</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-01T11:31:46.7441-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20197</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20197</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20197</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The routine use of ancillary studies is reshaping the practice of cytopathology. Currently, most cytopathologists recognize the importance of immunocytochemistry and molecular techniques as adjuncts to morphology to achieve a precise diagnosis. Cytopathologists also are expected to include specific prognostic and predictive information in their reports. The objective of this review was to address the use of immunocytochemistry and molecular techniques to refine the preoperative diagnosis and classification of lung cancer, thyroid cancer, kidney cancer, gastrointestinal cancer, and soft tissue tumors. Fine-needle aspiration also offers a suitable alternative to biopsy in a variety of clinical settings, in particular, when it may be useful to obtain material to study prognostic and predictive markers. This is particularly relevant to obtain material from metastatic sites. The study of KRAS in colon cancer, CKIT in gastrointestinal stromal tumors, and epidermal growth factor receptor mutational status in lung cancer also are addressed particularly in this report. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</p></div>]]></content:encoded><description>The routine use of ancillary studies is reshaping the practice of cytopathology. Currently, most cytopathologists recognize the importance of immunocytochemistry and molecular techniques as adjuncts to morphology to achieve a precise diagnosis. Cytopathologists also are expected to include specific prognostic and predictive information in their reports. The objective of this review was to address the use of immunocytochemistry and molecular techniques to refine the preoperative diagnosis and classification of lung cancer, thyroid cancer, kidney cancer, gastrointestinal cancer, and soft tissue tumors. Fine-needle aspiration also offers a suitable alternative to biopsy in a variety of clinical settings, in particular, when it may be useful to obtain material to study prognostic and predictive markers. This is particularly relevant to obtain material from metastatic sites. The study of KRAS in colon cancer, CKIT in gastrointestinal stromal tumors, and epidermal growth factor receptor mutational status in lung cancer also are addressed particularly in this report. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20195" xmlns="http://purl.org/rss/1.0/"><title>Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology</title><link>http://dx.doi.org/10.1002%2Fcncy.20195</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Massimo Bongiovanni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefano Crippa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zubair Baloch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simonetta Piana</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Spitale</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fabio Pagni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Mazzucchelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Camillo Di Bella</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William Faquin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-13T14:13:35.883969-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20195</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20195</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20195</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>At present, thyroid fine-needle aspiration (FNA) specimens are diagnosed using a tiered classification scheme, with the most popular of these being the 5-tiered and 6-tiered systems. In this study, the authors present their institutional experiences using these 2 different systems and evaluate their efficacy based on the surgical follow-up.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Thyroid FNA specimens and their corresponding surgical resection specimens were collected between 2007 and 2009. The following diagnostic categories are used in both systems: unsatisfactory/nondiagnostic, benign, follicular neoplasm/suspicious for follicular neoplasm, suspicious for malignancy, and malignant. An additional category termed atypia of undetermined significance/follicular lesion of undetermined significance was used for atypical cases in the 6-tiered system. Statistical analysis was performed by comparing the different diagnostic categories.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>The case cohort included a total of 7686 thyroid FNA specimens representing 3962 nodules and 3724 nodules, respectively, in the 5-tiered and 6-tiered systems. Negative predictive values for the benign categories (96.9% vs 97.5%; <em>P</em> = 1) and positive predictive values for both the follicular neoplasm categories (26.5% vs 32.1%; <em>P</em> = .2531) and the malignant categories (99.1% vs 99.4%; <em>P</em> = 1) were similar. The most significant differences between the 5-tiered and 6-tiered systems were the percentage of cases classified as benign (83.9% vs 55.4%; <em>P</em> &lt; .0001) and as follicular neoplasms (4.6% vs 23.8%; <em>P</em> &lt; .0001). It is interesting to note that fewer patients were referred for surgery in the 5-tiered system compared with the 6-tiered one (9.1% vs 36.5%; <em>P</em> &lt; .0001).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Use of either the 5-tiered or 6-tiered reporting systems for thyroid FNA specimens can potentially affect the clinical management of patients with thyroid nodules. Cancer (Cancer Cytopathol) 2011. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:At present, thyroid fine-needle aspiration (FNA) specimens are diagnosed using a tiered classification scheme, with the most popular of these being the 5-tiered and 6-tiered systems. In this study, the authors present their institutional experiences using these 2 different systems and evaluate their efficacy based on the surgical follow-up.METHODS:Thyroid FNA specimens and their corresponding surgical resection specimens were collected between 2007 and 2009. The following diagnostic categories are used in both systems: unsatisfactory/nondiagnostic, benign, follicular neoplasm/suspicious for follicular neoplasm, suspicious for malignancy, and malignant. An additional category termed atypia of undetermined significance/follicular lesion of undetermined significance was used for atypical cases in the 6-tiered system. Statistical analysis was performed by comparing the different diagnostic categories.RESULTS:The case cohort included a total of 7686 thyroid FNA specimens representing 3962 nodules and 3724 nodules, respectively, in the 5-tiered and 6-tiered systems. Negative predictive values for the benign categories (96.9% vs 97.5%; P = 1) and positive predictive values for both the follicular neoplasm categories (26.5% vs 32.1%; P = .2531) and the malignant categories (99.1% vs 99.4%; P = 1) were similar. The most significant differences between the 5-tiered and 6-tiered systems were the percentage of cases classified as benign (83.9% vs 55.4%; P &lt; .0001) and as follicular neoplasms (4.6% vs 23.8%; P &lt; .0001). It is interesting to note that fewer patients were referred for surgery in the 5-tiered system compared with the 6-tiered one (9.1% vs 36.5%; P &lt; .0001).CONCLUSIONS:Use of either the 5-tiered or 6-tiered reporting systems for thyroid FNA specimens can potentially affect the clinical management of patients with thyroid nodules. Cancer (Cancer Cytopathol) 2011. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20191" xmlns="http://purl.org/rss/1.0/"><title>The potential for overuse of atypical thyroid diagnoses</title><link>http://dx.doi.org/10.1002%2Fcncy.20191</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The potential for overuse of atypical thyroid diagnoses</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Henry</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-16T10:39:50.411209-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20191</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20191</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20191</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The atypical follicular cell diagnosis in the new Bethesda System for Reporting Thyroid Cytopathology is a heterogeneous category without well-defined cellular criteria and has the potential for overuse. Laboratories should monitor the use of this diagnosis.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>See also pages 000-000.</p></div>]]></content:encoded><description>The atypical follicular cell diagnosis in the new Bethesda System for Reporting Thyroid Cytopathology is a heterogeneous category without well-defined cellular criteria and has the potential for overuse. Laboratories should monitor the use of this diagnosis.See also pages 000-000.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20192" xmlns="http://purl.org/rss/1.0/"><title>The atypia of undetermined significance/follicular lesion of undetermined significance: Malignant ratio</title><link>http://dx.doi.org/10.1002%2Fcncy.20192</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The atypia of undetermined significance/follicular lesion of undetermined significance: Malignant ratio</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey F. Krane</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul A. VanderLaan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William C. Faquin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew A. Renshaw</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-14T09:12:13.585759-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20192</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20192</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20192</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>The Bethesda System (TBS) for reporting thyroid cytopathology introduced the atypia of undetermined significance/follicular lesion of undetermined significance (AUS) category, but did not provide adequate guidance for the appropriate use of this diagnosis. In the current study, the authors sought to identify an appropriate measure for AUS use based on experience to date with TBS.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>The authors reviewed 8 series, including their own laboratory experiences, with a total of 30,466 thyroid aspirates classified within TBS.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>The median AUS rate was 9.9% with a range of 3.0% to 18.0%. Use of the individual diagnostic categories within TBS varied up to 12.7-fold. The ratio of “suspicious for follicular neoplasm” plus “suspicious for malignancy” to “malignant” (M) diagnoses varied the least (1.8-fold). The AUS:M ratio provided a suitable measure of assessing AUS use, with a median ratio of 2.0 and a range of 0.5 to 4.9.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Based on available studies, an AUS:M ratio of 1.0 to 3.0 is recommended. AUS:M ratios &gt; 3.0 are likely because of overdiagnosis of AUS or underdiagnosis of M. AUS:M ratios &lt; 1.0 are mostly due to low AUS rates, at the likely expense of sensitivity. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:The Bethesda System (TBS) for reporting thyroid cytopathology introduced the atypia of undetermined significance/follicular lesion of undetermined significance (AUS) category, but did not provide adequate guidance for the appropriate use of this diagnosis. In the current study, the authors sought to identify an appropriate measure for AUS use based on experience to date with TBS.METHODS:The authors reviewed 8 series, including their own laboratory experiences, with a total of 30,466 thyroid aspirates classified within TBS.RESULTS:The median AUS rate was 9.9% with a range of 3.0% to 18.0%. Use of the individual diagnostic categories within TBS varied up to 12.7-fold. The ratio of “suspicious for follicular neoplasm” plus “suspicious for malignancy” to “malignant” (M) diagnoses varied the least (1.8-fold). The AUS:M ratio provided a suitable measure of assessing AUS use, with a median ratio of 2.0 and a range of 0.5 to 4.9.CONCLUSIONS:Based on available studies, an AUS:M ratio of 1.0 to 3.0 is recommended. AUS:M ratios &gt; 3.0 are likely because of overdiagnosis of AUS or underdiagnosis of M. AUS:M ratios &lt; 1.0 are mostly due to low AUS rates, at the likely expense of sensitivity. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20184" xmlns="http://purl.org/rss/1.0/"><title>On-site adequacy evaluations performed by cytotechnologists</title><link>http://dx.doi.org/10.1002%2Fcncy.20184</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">On-site adequacy evaluations performed by cytotechnologists</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Oname O. Burlingame</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kessé O. Kessé</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stuart G. Silverman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edmund S. Cibas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-08-31T13:09:55.017589-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20184</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20184</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20184</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Practice patterns regarding on-site assessment of the adequacy of image-guided fine needle aspiration biopsies (FNABs) vary among laboratories, but in many laboratories primary responsibility rests with the cytotechnologists. On-site evaluation provides feedback on the need for additional passes and facilitates triaging of the specimen for time-sensitive ancillary studies. Prior studies have suggested that cytotechnologists can assess the initially obtained specimens correctly, but they are few in number and limited by small size. The purpose of this study was to assess the frequency with which our cytotechnologists were able to correctly assess specimens as adequate using a large-scale database that included a wide range of image-guided FNABs.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>The frequency that on-site adequacy assessments of 5241 image-guided FNABs were correct was determined by correlating the cytotechnologists' assessments of adequacy with the final cytologic interpretation. An adequacy assessment was considered correct if the FNAB was ultimately reported as satisfactory and unequivocally benign or malignant. An adequate reading on a case that was ultimately reported as unsatisfactory, atypical, or suspicious was deemed “incorrect.” The effect of imaging modality was also analyzed.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Of 5241 FNABs, 2784 (53%) were interpreted as adequate on site. Of these, 2637 (95%) were correctly considered adequate. Of the common biopsy sites sampled, the adequacy assessments for liver FNABs demonstrated the highest frequency for being correctly considered adequate (97%) and those for kidney FNABs showed the lowest (90%). Imaging modality had no effect on accuracy.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Cytotechnologists are almost always correct when assessing initial FNAB samples as adequate. Cancer (Cancer Cytopathol) 2011. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Practice patterns regarding on-site assessment of the adequacy of image-guided fine needle aspiration biopsies (FNABs) vary among laboratories, but in many laboratories primary responsibility rests with the cytotechnologists. On-site evaluation provides feedback on the need for additional passes and facilitates triaging of the specimen for time-sensitive ancillary studies. Prior studies have suggested that cytotechnologists can assess the initially obtained specimens correctly, but they are few in number and limited by small size. The purpose of this study was to assess the frequency with which our cytotechnologists were able to correctly assess specimens as adequate using a large-scale database that included a wide range of image-guided FNABs.METHODS:The frequency that on-site adequacy assessments of 5241 image-guided FNABs were correct was determined by correlating the cytotechnologists' assessments of adequacy with the final cytologic interpretation. An adequacy assessment was considered correct if the FNAB was ultimately reported as satisfactory and unequivocally benign or malignant. An adequate reading on a case that was ultimately reported as unsatisfactory, atypical, or suspicious was deemed “incorrect.” The effect of imaging modality was also analyzed.RESULTS:Of 5241 FNABs, 2784 (53%) were interpreted as adequate on site. Of these, 2637 (95%) were correctly considered adequate. Of the common biopsy sites sampled, the adequacy assessments for liver FNABs demonstrated the highest frequency for being correctly considered adequate (97%) and those for kidney FNABs showed the lowest (90%). Imaging modality had no effect on accuracy.CONCLUSIONS:Cytotechnologists are almost always correct when assessing initial FNAB samples as adequate. Cancer (Cancer Cytopathol) 2011. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20187" xmlns="http://purl.org/rss/1.0/"><title>Implementation of FocalPoint GS location-guided imaging system</title><link>http://dx.doi.org/10.1002%2Fcncy.20187</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Implementation of FocalPoint GS location-guided imaging system</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Angelique W. Levi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David C. Chhieng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kevin Schofield</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Diane Kowalski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Malini Harigopal</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-08-25T09:59:12.459072-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20187</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20187</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20187</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background:</h3><div class="para"><p>Recently, the Food and Drug Administration approved the use of the location-guided imaging system FocalPoint GS (FPGS), on SurePath Papanicolaou (Pap) tests for primary screening. The objective of the current study was to evaluate the impact of FPGS on the following: distribution of diagnostic categories; rate of high-risk human papillomavirus (HR-HPV)–positive ASC-US cases; and quality control (QC) data before and after FPGS implementation.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods:</h3><div class="para"><p>A search of the laboratory information system was performed to identify all SurePath Pap tests processed in our laboratory for the first 19 months after FPGS implementation. We also retrieved all SurePath specimens from a 16-month period prior to FPGS implementation to serve as the control. During the period from Janaury 2008 to April 2009, the FocalPoint Slide Profiler was used.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results:</h3><div class="para"><p>Implementation of FPGS resulted in a significantly higher percentage of LSIL and ASC-US interpretations, as well as a significant increase in the detection of candidiasis and bacterial vaginosis. The ASC-to-SIL ratio was 1.4 and 1.9 before and after FPGS implementation, respectively. There was a decrease in the HR-HPV positive rate in ASC-US cases, and a decrease in the estimated false-negative fraction after FPGS implementation.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions:</h3><div class="para"><p>In conclusion, our study seems to demonstrate a favorable performance of FPGS in the routine clinical setting. FPGS may have the potential to be a promising screening tool for gynecologic cytology in a low-risk patient population. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>Background:Recently, the Food and Drug Administration approved the use of the location-guided imaging system FocalPoint GS (FPGS), on SurePath Papanicolaou (Pap) tests for primary screening. The objective of the current study was to evaluate the impact of FPGS on the following: distribution of diagnostic categories; rate of high-risk human papillomavirus (HR-HPV)–positive ASC-US cases; and quality control (QC) data before and after FPGS implementation.Methods:A search of the laboratory information system was performed to identify all SurePath Pap tests processed in our laboratory for the first 19 months after FPGS implementation. We also retrieved all SurePath specimens from a 16-month period prior to FPGS implementation to serve as the control. During the period from Janaury 2008 to April 2009, the FocalPoint Slide Profiler was used.Results:Implementation of FPGS resulted in a significantly higher percentage of LSIL and ASC-US interpretations, as well as a significant increase in the detection of candidiasis and bacterial vaginosis. The ASC-to-SIL ratio was 1.4 and 1.9 before and after FPGS implementation, respectively. There was a decrease in the HR-HPV positive rate in ASC-US cases, and a decrease in the estimated false-negative fraction after FPGS implementation.Conclusions:In conclusion, our study seems to demonstrate a favorable performance of FPGS in the routine clinical setting. FPGS may have the potential to be a promising screening tool for gynecologic cytology in a low-risk patient population. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20178" xmlns="http://purl.org/rss/1.0/"><title>The atypical thyroid fine-needle aspiration: Past, present, and future</title><link>http://dx.doi.org/10.1002%2Fcncy.20178</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The atypical thyroid fine-needle aspiration: Past, present, and future</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Massimo Bongiovanni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey F. Krane</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edmund S. Cibas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William C. Faquin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-07-12T15:27:28.246265-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20178</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20178</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20178</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Thyroid fine-needle aspiration has developed into a key test in the evaluation of thyroid nodules. Although the interpretation of thyroid aspirates containing mild abnormalities is problematic, the introduction of the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has helped to delineate such cases in a systematic and clinically meaningful manner. Herein the authors review the cytomorphologic features associated with the AUS/FLUS interpretation and summarize the results of studies conducted since the implementation of TBSRTC. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</p></div>]]></content:encoded><description>Thyroid fine-needle aspiration has developed into a key test in the evaluation of thyroid nodules. Although the interpretation of thyroid aspirates containing mild abnormalities is problematic, the introduction of the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has helped to delineate such cases in a systematic and clinically meaningful manner. Herein the authors review the cytomorphologic features associated with the AUS/FLUS interpretation and summarize the results of studies conducted since the implementation of TBSRTC. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20181" xmlns="http://purl.org/rss/1.0/"><title>The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms</title><link>http://dx.doi.org/10.1002%2Fcncy.20181</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George R. Collins</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jaiyeola Thomas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Neelam Joshi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Songlin Zhang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-07-12T15:26:39.902073-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20181</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20181</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20181</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>To the authors' knowledge, the diagnostic value of cell block (CB) as an adjunct to ThinPrep liquid-based cytology (LBC) of bronchial washing specimens in the detection and subclassification of pulmonary neoplasms has not been well evaluated. The objective of the current study was to evaluate the diagnostic utility of CB in this setting.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>A total of 74 bronchial washing specimens and concurrently prepared CBs with a diagnosis of malignant or suspicious/atypical obtained from bronchoscopy procedures performed during 2009 were reviewed along with 28 randomly selected negative cases. LBC and CBs were reviewed independently. Deeper levels and ancillary studies were performed on CBs for specific tumor classification if needed. LBC and CB diagnoses were correlated with final histology and/or bronchial brushings.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Use of CBs increased the number of positive diagnoses from 18 (LBC only) to 30 (combined LBC and CB) and 36 (combined LBC and CB with ancillary studies), with increased diagnostic yields of 67% and 100%, respectively. CB without ancillary techniques detected 22 malignancies whereas LBC detected 18 malignancies and CB with ancillary techniques detected 29 malignancies. A specific tumor diagnosis was possible in 22 of 29 (76%) malignancies detected by CB. Bronchial brushings and histology confirmed malignancy in 91% and 92% of cases, respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>CB combined with LBC was found to improve the rate of detection of malignancy over LBC alone, especially in cases with suspicious or atypical LBC diagnoses. Increased diagnostic yield is observed when CB is used with or without ancillary studies, but the yield is higher with CB using ancillary studies. CB serves as yet another available source of diagnostic material for immunohistochemical and molecular studies. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:To the authors' knowledge, the diagnostic value of cell block (CB) as an adjunct to ThinPrep liquid-based cytology (LBC) of bronchial washing specimens in the detection and subclassification of pulmonary neoplasms has not been well evaluated. The objective of the current study was to evaluate the diagnostic utility of CB in this setting.METHODS:A total of 74 bronchial washing specimens and concurrently prepared CBs with a diagnosis of malignant or suspicious/atypical obtained from bronchoscopy procedures performed during 2009 were reviewed along with 28 randomly selected negative cases. LBC and CBs were reviewed independently. Deeper levels and ancillary studies were performed on CBs for specific tumor classification if needed. LBC and CB diagnoses were correlated with final histology and/or bronchial brushings.RESULTS:Use of CBs increased the number of positive diagnoses from 18 (LBC only) to 30 (combined LBC and CB) and 36 (combined LBC and CB with ancillary studies), with increased diagnostic yields of 67% and 100%, respectively. CB without ancillary techniques detected 22 malignancies whereas LBC detected 18 malignancies and CB with ancillary techniques detected 29 malignancies. A specific tumor diagnosis was possible in 22 of 29 (76%) malignancies detected by CB. Bronchial brushings and histology confirmed malignancy in 91% and 92% of cases, respectively.CONCLUSIONS:CB combined with LBC was found to improve the rate of detection of malignancy over LBC alone, especially in cases with suspicious or atypical LBC diagnoses. Increased diagnostic yield is observed when CB is used with or without ancillary studies, but the yield is higher with CB using ancillary studies. CB serves as yet another available source of diagnostic material for immunohistochemical and molecular studies. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.21187" xmlns="http://purl.org/rss/1.0/"><title>Comparative effectiveness research takes a stand on cancer screening</title><link>http://dx.doi.org/10.1002%2Fcncy.21187</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparative effectiveness research takes a stand on cancer screening</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryn Nelson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.21187</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.21187</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.21187</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">CytoSource</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">2</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20196" xmlns="http://purl.org/rss/1.0/"><title>New applications for old assays and the importance of validation</title><link>http://dx.doi.org/10.1002%2Fcncy.20196</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">New applications for old assays and the importance of validation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jennifer L. Hunt</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20196</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20196</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20196</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">3</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">6</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The author discusses the importance of human papillomavirus testing, the selection of assay type, and assay validation.</p></div>]]></content:encoded><description>The author discusses the importance of human papillomavirus testing, the selection of assay type, and assay validation.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20186" xmlns="http://purl.org/rss/1.0/"><title>Cytologic and molecular diagnosis of thyroid cancers</title><link>http://dx.doi.org/10.1002%2Fcncy.20186</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cytologic and molecular diagnosis of thyroid cancers</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lewis A. Hassell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth M. Gillies</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Terence Dunn</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20186</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20186</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20186</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">7</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">17</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The Bethesda system for standardized reporting of thyroid fine needle aspiration (FNA) cytology has positively affected the clarity of communication of results and management of patients evaluated for thyroid nodules. Problematic areas still exist in the triage of some of these samples, particularly those in the categories of “follicular lesion with atypia of uncertain significance” and “follicular lesion.” The literature on molecular and genetic abnormalities in thyroid lesions is reviewed. Potentially useful markers for distinguishing currently problematic categories of FNA cytologic samples, especially nondiagnostic samples, atypia of uncertain significance, and follicular lesions, are discussed. The predictive value of the respective molecular analyses in these settings is examined. Evaluation of FNA samples with negative or suboptimal follicular cytology for Ras mutations may be useful in detecting potentially significant follicular lesions (carcinomas) but is quite low in overall yield. Cytologic samples with atypia of uncertain significance, which may include the possibility of papillary carcinomas, may be fruitfully evaluated using a panel of molecular tests for <em>BRAF, RET</em>/PTC, <em>PAX8</em>/<em>PPARG1</em>, and Ras. Other markers also have potential utility in the workup of thyroid lesions. An era of combined modality testing in thyroid cytology is emerging in which classical cytologic findings can be coupled with molecular data to increase the predictive power of diagnostic interpretations; however, there remains a group of atypical cytologic samples negative for known molecular markers in which the risk of malignancy is too high to simply follow expectantly. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div>]]></content:encoded><description>The Bethesda system for standardized reporting of thyroid fine needle aspiration (FNA) cytology has positively affected the clarity of communication of results and management of patients evaluated for thyroid nodules. Problematic areas still exist in the triage of some of these samples, particularly those in the categories of “follicular lesion with atypia of uncertain significance” and “follicular lesion.” The literature on molecular and genetic abnormalities in thyroid lesions is reviewed. Potentially useful markers for distinguishing currently problematic categories of FNA cytologic samples, especially nondiagnostic samples, atypia of uncertain significance, and follicular lesions, are discussed. The predictive value of the respective molecular analyses in these settings is examined. Evaluation of FNA samples with negative or suboptimal follicular cytology for Ras mutations may be useful in detecting potentially significant follicular lesions (carcinomas) but is quite low in overall yield. Cytologic samples with atypia of uncertain significance, which may include the possibility of papillary carcinomas, may be fruitfully evaluated using a panel of molecular tests for BRAF, RET/PTC, PAX8/PPARG1, and Ras. Other markers also have potential utility in the workup of thyroid lesions. An era of combined modality testing in thyroid cytology is emerging in which classical cytologic findings can be coupled with molecular data to increase the predictive power of diagnostic interpretations; however, there remains a group of atypical cytologic samples negative for known molecular markers in which the risk of malignancy is too high to simply follow expectantly. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20175" xmlns="http://purl.org/rss/1.0/"><title>Application of the Hybrid Capture 2 assay to squamous cell carcinomas of the head and neck</title><link>http://dx.doi.org/10.1002%2Fcncy.20175</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Application of the Hybrid Capture 2 assay to squamous cell carcinomas of the head and neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Justin A. Bishop</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zahra Maleki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandra Valsamakis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takenori Ogawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaofei Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sara I. Pai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William H. Westra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20175</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20175</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20175</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">18</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">25</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>A growing proportion of head and neck squamous cell carcinoma (HNSCC) is caused by the human papillomavirus (HPV). In light of the unique natural history and prognosis of HPV-related HNSCCs, routine HPV testing is being incorporated into diagnostic protocols. Accordingly, there is an escalating demand for an optimal detection strategy that is sensitive and specific, transferrable to the diagnostic laboratory, standardized across laboratories, cost-effective, and amenable to broad application across specimen types including cytologic preparations.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Cytologic preparations (fine-needle aspirates [FNAs] and brushes) were obtained from surgically resected HNSCCs and evaluated for the presence of high-risk HPV using the Hybrid Capture 2 assay. HPV analysis was also performed on the corresponding tissue sections using HPV in situ hybridization and p16 immunohistochemistry. In cases in which the immunohistochemical and in situ hybridization results were discordant, HPV status was determined by real-time polymerase chain reaction detection of E7 expression. HPV status in the tissues and corresponding cytologic samples was compared.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Based on benchmark HPV testing of the tissue sections, 14 HNSCCs were classified as HPV positive and 10 as HPV negative. All corresponding cytologic preparations were correctly classified using the Hybrid Capture 2 assay.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>The Hybrid Capture 2 strategy, already widely used for the detection of high-risk HPV in cervical brushes, is readily transferrable to HNSCCs. Consistent accuracy in cytologic preparation suggests its potential application in FNAs from patients who present with lymph node metastases, and may eliminate the need to obtain tissue solely for the purpose of HPV testing. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:A growing proportion of head and neck squamous cell carcinoma (HNSCC) is caused by the human papillomavirus (HPV). In light of the unique natural history and prognosis of HPV-related HNSCCs, routine HPV testing is being incorporated into diagnostic protocols. Accordingly, there is an escalating demand for an optimal detection strategy that is sensitive and specific, transferrable to the diagnostic laboratory, standardized across laboratories, cost-effective, and amenable to broad application across specimen types including cytologic preparations.METHODS:Cytologic preparations (fine-needle aspirates [FNAs] and brushes) were obtained from surgically resected HNSCCs and evaluated for the presence of high-risk HPV using the Hybrid Capture 2 assay. HPV analysis was also performed on the corresponding tissue sections using HPV in situ hybridization and p16 immunohistochemistry. In cases in which the immunohistochemical and in situ hybridization results were discordant, HPV status was determined by real-time polymerase chain reaction detection of E7 expression. HPV status in the tissues and corresponding cytologic samples was compared.RESULTS:Based on benchmark HPV testing of the tissue sections, 14 HNSCCs were classified as HPV positive and 10 as HPV negative. All corresponding cytologic preparations were correctly classified using the Hybrid Capture 2 assay.CONCLUSIONS:The Hybrid Capture 2 strategy, already widely used for the detection of high-risk HPV in cervical brushes, is readily transferrable to HNSCCs. Consistent accuracy in cytologic preparation suggests its potential application in FNAs from patients who present with lymph node metastases, and may eliminate the need to obtain tissue solely for the purpose of HPV testing. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20188" xmlns="http://purl.org/rss/1.0/"><title>Immunocytochemical colocalization of p16INK4a and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma</title><link>http://dx.doi.org/10.1002%2Fcncy.20188</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Immunocytochemical colocalization of p16INK4a and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meenakshi Singh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel Mockler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ali Akalin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephanie Burke</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Laurie Shroyer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kenneth R. Shroyer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20188</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20188</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20188</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">26</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">34</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Although previous studies have shown that p16<sup>INK4a</sup> and Ki-67 are sensitive and specific markers for high-grade lesions (≥CIN2) on cervical biopsies, limited information is available regarding the performance of a dual-staining approach as a diagnostic adjunct in cervical cytology. We evaluated a dual p16<sup>INK4a</sup>/Ki-67 immunocytochemistry (ICC) assay to determine its sensitivity and specificity versus that of high-risk HPV (HR-HPV) in a US-based pilot cytology study.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>ThinPrep specimens from 122 cervical cytology specimens encompassing 23 negative (NILM), 20 ASC-US, 22 LSIL, 17 ASCH, 22 HSIL, and 18 AGC cases were processed for multiplexed ICC staining using a CINtec Plus Kit. Dual-positive assay results were defined based on the detection of 1 or more epithelial cells that were stained for both p16<sup>INK4a</sup> and Ki-67 without regard to cellular morphology. HR-HPV testing was performed by multiplex PCR with capillary electrophoresis genotyping.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Dual staining for p16<sup>INK4a</sup> and Ki-67 was frequently detected in HSIL and AGC but was rarely detected in NILM cases. The HR-HPV assay showed a sensitivity of 76.2% and a specificity of 55.8% for the detection of clinically significant cervical squamous or endometrial lesions. In contrast, the colocalization of p16<sup>INK4a</sup> plus Ki-67 maintained a high sensitivity of 81.8% and improved specificity to 81.8% for biopsy-confirmed CIN2/3, endocervical adenocarcinoma, or endometrial adenocarcinoma.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Dual staining for p16<sup>INK4a</sup>/Ki-67 immunocytochemistry dramatically increased specificity and maintained high-level sensitivity for the diagnosis of CIN2/3 or glandular lesions compared with PCR-based testing for HR-HPV. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Although previous studies have shown that p16INK4a and Ki-67 are sensitive and specific markers for high-grade lesions (≥CIN2) on cervical biopsies, limited information is available regarding the performance of a dual-staining approach as a diagnostic adjunct in cervical cytology. We evaluated a dual p16INK4a/Ki-67 immunocytochemistry (ICC) assay to determine its sensitivity and specificity versus that of high-risk HPV (HR-HPV) in a US-based pilot cytology study.METHODS:ThinPrep specimens from 122 cervical cytology specimens encompassing 23 negative (NILM), 20 ASC-US, 22 LSIL, 17 ASCH, 22 HSIL, and 18 AGC cases were processed for multiplexed ICC staining using a CINtec Plus Kit. Dual-positive assay results were defined based on the detection of 1 or more epithelial cells that were stained for both p16INK4a and Ki-67 without regard to cellular morphology. HR-HPV testing was performed by multiplex PCR with capillary electrophoresis genotyping.RESULTS:Dual staining for p16INK4a and Ki-67 was frequently detected in HSIL and AGC but was rarely detected in NILM cases. The HR-HPV assay showed a sensitivity of 76.2% and a specificity of 55.8% for the detection of clinically significant cervical squamous or endometrial lesions. In contrast, the colocalization of p16INK4a plus Ki-67 maintained a high sensitivity of 81.8% and improved specificity to 81.8% for biopsy-confirmed CIN2/3, endocervical adenocarcinoma, or endometrial adenocarcinoma.CONCLUSIONS:Dual staining for p16INK4a/Ki-67 immunocytochemistry dramatically increased specificity and maintained high-level sensitivity for the diagnosis of CIN2/3 or glandular lesions compared with PCR-based testing for HR-HPV. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20185" xmlns="http://purl.org/rss/1.0/"><title>Predicting pulmonary adenocarcinoma outcome based on a cytology grading system</title><link>http://dx.doi.org/10.1002%2Fcncy.20185</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Predicting pulmonary adenocarcinoma outcome based on a cytology grading system</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlie S. Sigel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dorota E. Rudomina</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Camelia S. Sima</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Natasha Rekhtman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William D. Travis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kim R. Geisinger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andre L. Moreira</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20185</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20185</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20185</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">35</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">43</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Pulmonary adenocarcinoma (AD) has a variety of architectural patterns. Recently, a 3-tiered histological pattern-based grading system was developed for stage I lung AD, stratifying patients into low, intermediate, and high risk for recurrence. However, cytology may serve as the primary method for diagnosis in patients with inoperable disease. Attempts to correlate architecture between parallel cytological and histological preparations have not been successful. Therefore, we evaluated cytomorphologic features of previously histologically graded AD to identify features of potential prognostic significance.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>One hundred and thirteen fine-needle aspirations with excised adenocarcinomas were reviewed. In the liquid-based preparation, we evaluated cell arrangements (flat sheets vs 3-D clusters vs single cells), nuclear features (size variability, shape, and contour), nucleoli (prominent or inconspicuous), presence of nuclear inclusions, chromatin (fine, coarse, or clumped), and quality of background. The features were tested by multivariate analysis to identify associations with histological grade and disease-free survival (DFS), and a cytological score was generated.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Nuclear size, chromatin pattern, and nuclear contours showed a significant association with histological grade and DFS. These features were included in the composite cytological score (range, 0-5). By grouping the cytological scores, we stratified the tumors into low (median DFS, 100%), intermediate (median DFS, 78%), and high (median DFS, 55%) rate of recurrence (<em>P</em> = .008). There was a good correlation with the histological grading system.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>In liquid-based preparations, distinctive cytological features of pulmonary adenocarcinoma correlate with levels of histological differentiation and can be combined into a score with prognostic significance. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Pulmonary adenocarcinoma (AD) has a variety of architectural patterns. Recently, a 3-tiered histological pattern-based grading system was developed for stage I lung AD, stratifying patients into low, intermediate, and high risk for recurrence. However, cytology may serve as the primary method for diagnosis in patients with inoperable disease. Attempts to correlate architecture between parallel cytological and histological preparations have not been successful. Therefore, we evaluated cytomorphologic features of previously histologically graded AD to identify features of potential prognostic significance.METHODS:One hundred and thirteen fine-needle aspirations with excised adenocarcinomas were reviewed. In the liquid-based preparation, we evaluated cell arrangements (flat sheets vs 3-D clusters vs single cells), nuclear features (size variability, shape, and contour), nucleoli (prominent or inconspicuous), presence of nuclear inclusions, chromatin (fine, coarse, or clumped), and quality of background. The features were tested by multivariate analysis to identify associations with histological grade and disease-free survival (DFS), and a cytological score was generated.RESULTS:Nuclear size, chromatin pattern, and nuclear contours showed a significant association with histological grade and DFS. These features were included in the composite cytological score (range, 0-5). By grouping the cytological scores, we stratified the tumors into low (median DFS, 100%), intermediate (median DFS, 78%), and high (median DFS, 55%) rate of recurrence (P = .008). There was a good correlation with the histological grading system.CONCLUSIONS:In liquid-based preparations, distinctive cytological features of pulmonary adenocarcinoma correlate with levels of histological differentiation and can be combined into a score with prognostic significance. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20179" xmlns="http://purl.org/rss/1.0/"><title>Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule</title><link>http://dx.doi.org/10.1002%2Fcncy.20179</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guhyun Kang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eun Yoon Cho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jung Hee Shin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jae-Hoon Chung</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jong Won Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Young Lyun Oh</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20179</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20179</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20179</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">44</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">51</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Thyroid fine-needle aspiration (FNA) is the primary diagnostic tool used for the evaluation of thyroid nodules. Although most aspirates provide diagnostic cytology, some are classified as indeterminate. The aim of this study was to determine whether the second review of FNA cytology can improve the diagnostic values and to assess the role of proto-oncogene <em>B-Raf</em> (<em>BRAF</em>) mutation testing in the diagnosis of papillary carcinoma (PC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Thyroid aspirates from 1060 patients were submitted for cytologic evaluation and <em>BRAF</em>V600E mutation analysis. A second cytologic review was performed by 2 cytopathologists in light of the mutation status.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Of the 313 patients who received surgery, 200 (63.9%) had been initially diagnosed as malignant by cytology. They were surgically confirmed as PCs, and the <em>BRAF</em>V600E mutation was detected in 82.5% of the cases. Ninety-five of 102 cases (93.1%) with indeterminate cytology turned out to be malignant, and the mutation was present in 63.3% of PCs. The sensitivity, accuracy, and negative predictive value (NPV) of the second review were better than those of initial cytologic diagnosis (<em>P</em> &lt;.001). The addition of the mutation analysis significantly increased the sensitivity, accuracy, and NPV for detecting PCs compared with those of cytology alone.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Qualified cytologic diagnosis increases the effectiveness of FNA, forgoing the need for repeat biopsy or intraoperative frozen section evaluation. Preoperative <em>BRAF</em> mutation testing can supplement the routine cytology in the selection of thyroid nodules for surgery. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Thyroid fine-needle aspiration (FNA) is the primary diagnostic tool used for the evaluation of thyroid nodules. Although most aspirates provide diagnostic cytology, some are classified as indeterminate. The aim of this study was to determine whether the second review of FNA cytology can improve the diagnostic values and to assess the role of proto-oncogene B-Raf (BRAF) mutation testing in the diagnosis of papillary carcinoma (PC).METHODS:Thyroid aspirates from 1060 patients were submitted for cytologic evaluation and BRAFV600E mutation analysis. A second cytologic review was performed by 2 cytopathologists in light of the mutation status.RESULTS:Of the 313 patients who received surgery, 200 (63.9%) had been initially diagnosed as malignant by cytology. They were surgically confirmed as PCs, and the BRAFV600E mutation was detected in 82.5% of the cases. Ninety-five of 102 cases (93.1%) with indeterminate cytology turned out to be malignant, and the mutation was present in 63.3% of PCs. The sensitivity, accuracy, and negative predictive value (NPV) of the second review were better than those of initial cytologic diagnosis (P &lt;.001). The addition of the mutation analysis significantly increased the sensitivity, accuracy, and NPV for detecting PCs compared with those of cytology alone.CONCLUSIONS:Qualified cytologic diagnosis increases the effectiveness of FNA, forgoing the need for repeat biopsy or intraoperative frozen section evaluation. Preoperative BRAF mutation testing can supplement the routine cytology in the selection of thyroid nodules for surgery. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20180" xmlns="http://purl.org/rss/1.0/"><title>Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma</title><link>http://dx.doi.org/10.1002%2Fcncy.20180</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kim Hookim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael H. Roh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joseph Willman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeremiah Placido</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Helmut C. Weigelin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kristina L. Fields</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Judy Pang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryan L. Betz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stewart M. Knoepp</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20180</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20180</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20180</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">52</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">61</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>The cytodiagnosis of melanoma in fine-needle aspiration (FNA) specimens can be challenging, often requiring the use of immunocytochemistry. As constitutively activating mutations in the <em>BRAF</em> oncogene are present in at least 40% of melanomas, the use of FNA material to interrogate the <em>BRAF</em> mutational status is likely to increase. Because cell blocks, traditionally used for these studies, can occasionally exhibit insufficient tumor cellularity, the authors investigated the utility of direct smears for immunocytochemistry and <em>BRAF</em> mutational analysis.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>Immunocytochemistry for S-100, HMB-45, and Mart-1 was prospectively performed on direct smears in 17 FNAs of metastatic melanoma. Next, <em>BRAF</em> sequencing was performed using DNA isolated from archived Diff-Quik–stained direct smears for 15 cases. In parallel, sequencing was performed using DNA obtained from corresponding cell blocks.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>S-100 positivity in the tumor cells was observed in all 17 cases. HMB-45 and Mart-1 positivity was noted in 81% and 88% of cases, respectively. All 3 markers were positive in 76% of cases. Next, of the 15 archived melanoma FNAs tested, <em>BRAF</em> mutations were observed in 8 (53%); 5 and 3 melanomas harbored the V600E and V600K mutation, respectively. Corresponding cell blocks were also tested for all 15 cases, yielding concordant <em>BRAF</em> results in 14 (93%); 1 cell block yielded a false-negative result.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>Cytologic direct smears represent a robust and valuable source of cellular material for immunocytochemistry and molecular studies, especially in instances in which inadequate cell block cellularity is anticipated or encountered. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:The cytodiagnosis of melanoma in fine-needle aspiration (FNA) specimens can be challenging, often requiring the use of immunocytochemistry. As constitutively activating mutations in the BRAF oncogene are present in at least 40% of melanomas, the use of FNA material to interrogate the BRAF mutational status is likely to increase. Because cell blocks, traditionally used for these studies, can occasionally exhibit insufficient tumor cellularity, the authors investigated the utility of direct smears for immunocytochemistry and BRAF mutational analysis.METHODS:Immunocytochemistry for S-100, HMB-45, and Mart-1 was prospectively performed on direct smears in 17 FNAs of metastatic melanoma. Next, BRAF sequencing was performed using DNA isolated from archived Diff-Quik–stained direct smears for 15 cases. In parallel, sequencing was performed using DNA obtained from corresponding cell blocks.RESULTS:S-100 positivity in the tumor cells was observed in all 17 cases. HMB-45 and Mart-1 positivity was noted in 81% and 88% of cases, respectively. All 3 markers were positive in 76% of cases. Next, of the 15 archived melanoma FNAs tested, BRAF mutations were observed in 8 (53%); 5 and 3 melanomas harbored the V600E and V600K mutation, respectively. Corresponding cell blocks were also tested for all 15 cases, yielding concordant BRAF results in 14 (93%); 1 cell block yielded a false-negative result.CONCLUSIONS:Cytologic direct smears represent a robust and valuable source of cellular material for immunocytochemistry and molecular studies, especially in instances in which inadequate cell block cellularity is anticipated or encountered. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fcncy.20167" xmlns="http://purl.org/rss/1.0/"><title>Identification of tissue of origin in body fluid specimens using a gene expression microarray assay</title><link>http://dx.doi.org/10.1002%2Fcncy.20167</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Identification of tissue of origin in body fluid specimens using a gene expression microarray assay</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gregory A. Stancel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Donna Coffey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karla Alvarez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meredith Halks-Miller</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anita Lal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dina Mody</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tracy Koen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Todd Fairley</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Federico A. Monzon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-25T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/cncy.20167</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/cncy.20167</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fcncy.20167</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">62</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">70</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">BACKGROUND:</h3><div class="para"><p>Body fluid specimens may be the first and only pathologic specimen for clinical evaluation in metastatic cancer cases. The challenge of identifying the tissue of origin in metastatic cancer has led to the emergence of molecular-based assays, such as the microarray-based Pathwork Tissue of Origin gene expression test. The ability to use body fluid specimens in this test would be valuable in providing diagnoses to cancer patients without clearly identifiable primary sites. In the current study, the authors evaluated the Tissue of Origin Test for use with malignant effusion specimens.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">METHODS:</h3><div class="para"><p>A total of 27 metastasis-positive body fluid specimens from different body sites, including pleural, ascites, pericardial, and pelvic wash fluids, were obtained from patients with known diagnoses. Nine specimens from nonmalignant body fluids were included as controls. RNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue and gene expression analysis was performed with the Tissue of Origin Test.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">RESULTS:</h3><div class="para"><p>Seventeen of 27 metastasis-positive samples were non-necrotic with ≥60% tumor and yielded sufficient RNA. Of these samples, 94.1% (16 of 17) were in agreement with the available diagnosis. Of the 9 negative control samples evaluated, 7 (77.8%) demonstrated microarray expression profiles most similar to lymphoma, which is consistent with the predominance of inflammatory cells in these specimens.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CONCLUSIONS:</h3><div class="para"><p>The results of the current study demonstrated that FFPE cell blocks from cytologic body fluid specimens yield adequate diagnostic material for the Pathwork test and can be used in the workup of patients with unknown primary tumors. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</p></div></div>]]></content:encoded><description>BACKGROUND:Body fluid specimens may be the first and only pathologic specimen for clinical evaluation in metastatic cancer cases. The challenge of identifying the tissue of origin in metastatic cancer has led to the emergence of molecular-based assays, such as the microarray-based Pathwork Tissue of Origin gene expression test. The ability to use body fluid specimens in this test would be valuable in providing diagnoses to cancer patients without clearly identifiable primary sites. In the current study, the authors evaluated the Tissue of Origin Test for use with malignant effusion specimens.METHODS:A total of 27 metastasis-positive body fluid specimens from different body sites, including pleural, ascites, pericardial, and pelvic wash fluids, were obtained from patients with known diagnoses. Nine specimens from nonmalignant body fluids were included as controls. RNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue and gene expression analysis was performed with the Tissue of Origin Test.RESULTS:Seventeen of 27 metastasis-positive samples were non-necrotic with ≥60% tumor and yielded sufficient RNA. Of these samples, 94.1% (16 of 17) were in agreement with the available diagnosis. Of the 9 negative control samples evaluated, 7 (77.8%) demonstrated microarray expression profiles most similar to lymphoma, which is consistent with the predominance of inflammatory cells in these specimens.CONCLUSIONS:The results of the current study demonstrated that FFPE cell blocks from cytologic body fluid specimens yield adequate diagnostic material for the Pathwork test and can be used in the workup of patients with unknown primary tumors. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.</description></item></rdf:RDF>
